Loading
Lung Cancer Treatments and Mutations / Immunotherapy and Immune Responses · Journal article
Discover Oncology · August 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of a 77-year-old male with metastatic squamous cell lung cancer who achieved durable complete remission, including intracranial disease resolution, following one cycle of gemcitabine, carboplatin, and pembrolizumab. The authors acknowledge this outcome is 'exceedingly rare' and the report serves to document an unusual presentation rather than to establish a generalizable treatment benefit.
Single case report. A 77-year-old Turkish male, never-smoker, with hypertension and type 2 diabetes, history of urothelial carcinoma, presenting with metastatic squamous cell lung cancer with brain (paracentral and cerebellar) and pulmonary involvement.. Intervention: One cycle of gemcitabine, carboplatin, and pembrolizumab, following craniotomy and stereotactic radiosurgery for brain metastases.. Not specified.
Complete resolution of all lesions, including paracentral and cerebellar metastases and pulmonary nodules, documented on follow-up imaging after single cycle of chemoimmunotherapy Durable complete remission maintained at 24 months follow-up PD-L1 tumor proportion score 40%
Treatment-related toxicities (grade 2 fatigue and neutropenia, mild infection, grade 1 skin toxicity) resolved with supportive care
This case documents an unusually durable response to single-cycle chemoimmunotherapy in advanced SqCLC, but is explicitly characterized as 'exceedingly rare' and should not be interpreted as evidence of treatment efficacy in this population. The finding is noteworthy only as an outlier observation requiring confirmation in larger cohorts.
A single case report of an unusual clinical outcome in metastatic squamous cell lung cancer; descriptive rather than comparative, and explicitly noted as 'exceedingly rare', raising hypothesis about durability rather than establishing generalizable evidence.
As stated by the source record.
Quoted from the source exactly as published.
This case documents an unusually durable response to single-cycle chemoimmunotherapy in advanced SqCLC, but is explicitly characterized as 'exceedingly rare' and should not be interpreted as evidence of treatment efficacy in this population. The finding is noteworthy only as an outlier observation requiring confirmation in larger cohorts.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Squamous cell lung cancer (SqCLC) is an aggressive subtype of non-small cell lung cancer (NSCLC), frequently associated with distant metastases. Although immune checkpoint inhibitors improve survival, complete responses after a single cycle of pembrolizumab-based chemoimmunotherapy are exceedingly rare. A 77-year-old Turkish male with hypertension and type 2 diabetes presented with acute left arm weakness. He was a never-smoker with a history of urothelial carcinoma. Brain MRI revealed right paracentral and cerebellar metastatic lesions, while thoracic imaging showed multiple pulmonary nodules. Histopathology confirmed metastatic SqCLC with a PD-L1 tumor proportion score of 40%. The patient underwent craniotomy and stereotactic radiosurgery, followed by one cycle of gemcitabine, carboplatin, and pembrolizumab. Treatment-related toxicities (grade 2 fatigue, neutropenia, mild infection, and grade 1 skin toxicity) resolved with supportive care. Despite clinical stability, the patient declined further therapy. Follow-up imaging demonstrated complete resolution of all lesions. At 24 months, he remains in complete remission. This case illustrates a rare, durable complete response—including intracranial disease—after a single cycle of pembrolizumab-based chemoimmunotherapy in metastatic SqCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.